Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension

Hypertension

Volumn 33, Issue 6, 1999, Pages 1447-1452

  Sakata, Kazuyuki ^a   Shirotani, Manabu ^a   Yoshida, Hiroshi ^a   Nawada, Ryuzou ^a   Obayashi, Kazuhiko ^a   Togi, Kiyonori ^a   Miho, Narimasa ^a  

^a SHIZUOKA GENERAL HOSPITAL   (Japan)

Author keywords

Amlodipine; Calcium channels; Cilnidipine; Imaging; Plasma; Renin; Sympathetic nervous system

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; AMLODIPINE; CALCIUM ANTAGONIST; CALCIUM CHANNEL; CINITAPRIDE; NORADRENALIN; RENIN;

ADRENERGIC SYSTEM; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CALCIUM ANTAGONISM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFECT; ESSENTIAL HYPERTENSION; HEART; HEART SCINTISCANNING; HUMAN; NEUROENDOCRINE SYSTEM; NORADRENALIN BLOOD LEVEL; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL;

EID: 0033051158     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.33.6.1447     Document Type: Article

References (46)

1. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989;299: 1187-1192.
2. Ishikawa K, Nakai S, Takenaka T, Kanamasa K, Hama J, Ogawa I, Yamamoto T, Oyaizu M, Kimura A, Yamamoto K, Yabushita H, Katori R. Short-acting nifedipine and diltiazem do not reduce the incidence of cardiac events in patients with healed myocardial infarction Circulation. 1997;95:2368-2373.
3. Frohlich ED, McLoughlin MJ, Losem CJ, Ketelhut R; Messerli FH. Hemodynamic comparison of two nifedipine formulations in patients with essential hypertension. Am J Cardiol. 1991;68:1346-1350.
4. Esler M, Jennings G, Lambert G. Noradrenaline release and the pathophysiology of primary human hypertension. Am J Hypertens 1989;2: 140S-146S.
5. Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans: evidence from direct intraneural recordings. Hypertension. 1989;14:177-183.
6. Kuwahara T, Hamada M, Hiwada K. Direct evidence of impaired cardiac sympathetic innervation in essential hypertensive patients with left ventricular hypertrophy. J Nucl Med. 1998;39:1486-1491.
7. Sakata K, Shirotani M, Yoshida H, Kurata C. Comparison of effects of enalapril and nitrendipine on cardiac sympathetic nervous system in essential hypertension. J Am Coll Cardiol. 1998;32:438-443.
8. Alderman MH, Cohen HW, Roque R, Madhavan S. The risk of cardiovascular morbidity and mortality associated with calcium channel blockers in antihypertensive therapy. J Hypertens. 1996;14(suppl 1):S221.
9. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G. Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A, for Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-764.
10. Matsukawa T, Mano T, Gotoh E, Ishii M. Elevated sympathetic nerve activity in patients with accelerated essential hypertension. J Clin Invest. 1993;92:25-28.
11. Hamada T, Watanabe M, Kaneda T, Ohtahara A, Kinugawa T, Hisatome I, Fujimoto Y, Yoshida A, Shigemasa C. Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine. J Hypertens. 1998;16:111-118.
12. Minami J, Ishimitsu T, Kawano Y, Numabe A, Matsuoka H. Comparison of 24-hour blood pressure, heart rate, and autonomic nerve activity in hypertensive patients treated with cilnidipine or nifedipine retard. J Cardiovasc Pharmacol. 1998;32:331-336.
13. de Champlain J, Karas M, Nguyen P, Cartier P, Wistaff R, Toal CB, Nadeau R, Larochelle P. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients. J Hypertens. 1998;16:1357-1369.
14. Esler M, Jennings G, Korner P, Willett I, Dudley F, Hasking G, Anderson W, Lambert G. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension. 1988;11:3-20.
15. Kingwell BA, Thompson JM, Kaye DM, McPherson GA, Jennings GL, Esler MD. Heart rate spectral analysis, cardiac norepinephrine spillover, muscle sympathetic nerve activity during human sympathetic nervous activation and failure. Circulation. 1994;90:234-240.
16. Wenzel RR, Allegranza G, Binggeli C, Shaw S, Weidmann P, Luscher TF, Noll G. Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: role of pharmacokinetics. J Am Coll Cardiol. 1997;29:1607-1614.
17. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, Bourguignon MH, Bevenuti C, Duval AM, Agostini D, Loisance D, Castaigne A, Syrota A. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992;33: 471-477.
18. Schofer J, Spielmann R, Schuchert A, Weber K, Schluter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1988;12: 1252-1258.
19. Furukawa T, Nukada T, Suzuki K, Fujita Y, Mori Y, Nishimura M, Yamanaka M. Voltage and pH dependent block of cloned N-type Ca 2+ channels by amlodipine. Br J Pharmacol. 1997;121:1136-1140.
20. Uneyama H, Takahara A, Dohmoto H, Yoshimoto R, Inoue K, Akaike N. Blockade of N-type Ca2+ current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurones. Br J Pharmacol. 1997;122:37-42.
21. Yoshimoto R, Dohmoto H, Yamada K, Goto A. Prolonged inhibition of vascular contraction and calcium influx by the novel 1.4-dihydropyridine calcium antagonist cinaldipine (FRC-8653). Jpn J Pharmacol. 1991;56: 225-229.
22. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL. Effect of amlodipine on morbidity and mortality in severe chronic heart failure: Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996;335:1107-1114.
23. Guidelines Sub-Committee. 1993 Guidelines for the management of mild hypertension: memorandum from a WHO/ISH Meeting. J Hypertens. 1989;7:689-693.
24. Sakata K, Shirotani M, Yoshida H, Urano T, Takada Y, Takada A. Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension. Am Heart J. In press.
25. Julius S. Sympathetic hyperactivity and coronary risk in hypertension. Hypertension. 1993;21:886-893.
26. Mark AL. Sympathetic dysregulation in heart failure: mechanism and therapy. Clin Cardiol. 1995;18(suppl 1):I3-I8.
27. Cohn JN. Plasma norepinephrine and mortality. Clin Cardiol. 1995; 18(suppl 1):I9-I12.
28. Grossman E, Messerli FH. Effect of calcium antagonists on sympathetic activity. Eur Heart J. 1998;19(suppl F):F27-F31.
29. Nowycky MC, Fox AP, Tsien RW. Three types of neuronal calcium channel with different calcium agonist sensitivity. Nature. 1985;316: 440-443.
30. Uneyama H, Uchida H, Yoshimoto R, Ueno S, Inoue K, Akaike N. Effects of a novel antihypertensive drug, cilnidipine, on catecholamine secretion from differentiated PC12 cells. Hypertension 1998;31: 1195-1199.
31. Buhler FR. Cardiovascular care with new T-type calcium channel antagonist: possible role of attendant sympathetic nervous system inhibition. J Hypertens. 1997;15(suppl 5)S3-S7.
32. McCleskey EW, Fox Ap, Tsien RW. Omega-conotoxin, direct and persistent blockade of specific types of calcium channels in neurons but not muscle. Proc Natl Acad Sci U S A. 1987;84:4327-4331.
33. Pruneau D, Angus JA. Omega-conotoxin GVIA is a potent inhibitor of sympathetic neurogenic responses in rat small mesenteric arteries. Br J Pharmacol. 1990;100:180-184.
34. Saihara S, Sumio M, Hososno N, Hayashi Y, Kitamra Y, Hashimoto S. Effect of FRC-8653 (cilnidipine) on blood pressure changes during the cold pressor test. Jpn Pharmacol Ther. 1993;21:271-276.
35. Pedersen OL, Mikkelsen E, Christensen NJ, Komerup HJ, Penderson EB. Effect of nifedipine on plasma renin, aldosterone and catecholamines in arterial hypertension. Eur J Clin Pharmacol. 1979;15:235-240.
36. Fray JC, Lush DJ, Valentine AMD. Cellular mechanisms of renin secretion. Fed Proc. 1983;42:3150-3154.
37. Story DF, Ziogas J. Interaction of angiotensin with noradrenergic neuroeffector transmission. Trends Pharmacol Sci. 1987;8:269-271.
38. Ridker PM, Gaboury CL, Colin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation. 1993;87: 1969-1973.
39. Lind L, Lithell H, Wide L, Ljunghall S. Metabolic cardiovascular risk factors and the renin-aldosterone system in essential hypertension. J Hum Hypertens. 1992;6:27-29.
40. Kjeldlen SE, Rostrup M, Moan A, Mundal HH, Gjesdal K, Eide IK. The sympathetic nervous system may modulate the metabolic cardiovascular syndrome in essential hypertension. J Cardiovasc Pharmacol. 1992; 20(suppl 8):S32-S39.
41. Colucci WS, Williams GH, Alexander RW, Braunwald E. Mechanisms and implications of vasodilator tolerance in the treatment of congestive heart failure. Am J Med. 1981;71:89-99.
42. Iimura O, Kikuichi K, Shimamoto K, Nozawa A, Hasegawa R, Homma C, Komura H, Kobayakaea H. Effects of nisoldipine on sympathetic activity, the renin-angiotensin-aldosterone system, and water-sodium-calcium metabolism in patients with essential hypertension. Arzneim Forschung/Drug Res. 1989;39:710-714.
43. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
44. The SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
45. The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 316:1429-1435.
46. Ikeda K, Hosino M, Iida H, Ohnishi H. Antihypertensive and cardiovascular profiles of a newly synthesized dihydropyridine derivative 2-methoxyethyl(E)-3-phenyl-2-propen-1-yl(±)-1, 4-dihydro-2, 6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate**(FRC-8653). Pharmacometrics. 1992;44:433-442.